- Home
- PHAR vs BALY Comparison
PHAR vs BALY Comparison
Compare PHAR & BALY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- BALY
- Stock Information
- Founded
- PHAR 1988
- BALY 2004
- Country
- PHAR Netherlands
- BALY United States
- Employees
- PHAR N/A
- BALY 10000
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- BALY Hotels/Resorts
- Sector
- PHAR Health Care
- BALY Consumer Discretionary
- Exchange
- PHAR Nasdaq
- BALY Nasdaq
- Market Cap
- PHAR 731.1M
- BALY 737.4M
- IPO Year
- PHAR N/A
- BALY N/A
- Fundamental
- Price
- PHAR $10.00
- BALY $11.01
- Analyst Decision
- PHAR Strong Buy
- BALY Hold
- Analyst Count
- PHAR 3
- BALY 7
- Target Price
- PHAR $30.00
- BALY $18.00
- AVG Volume (30 Days)
- PHAR 3.6K
- BALY 363.4K
- Earning Date
- PHAR 07-31-2025
- BALY 02-19-2025
- Dividend Yield
- PHAR N/A
- BALY N/A
- EPS Growth
- PHAR N/A
- BALY N/A
- EPS
- PHAR N/A
- BALY N/A
- Revenue
- PHAR $320,708,000.00
- BALY $2,481,783,000.00
- Revenue This Year
- PHAR $13.31
- BALY $3.06
- Revenue Next Year
- PHAR $7.68
- BALY N/A
- P/E Ratio
- PHAR N/A
- BALY N/A
- Revenue Growth
- PHAR 24.13
- BALY 2.80
- 52 Week Low
- PHAR $6.65
- BALY $9.74
- 52 Week High
- PHAR $12.61
- BALY $18.38
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- BALY 54.77
- Support Level
- PHAR $9.99
- BALY $10.18
- Resistance Level
- PHAR $10.59
- BALY $11.60
- Average True Range (ATR)
- PHAR 0.35
- BALY 1.06
- MACD
- PHAR -0.14
- BALY 0.16
- Stochastic Oscillator
- PHAR 7.45
- BALY 29.81
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About BALY Bally's Corporation
Ballys Corp is a gaming, hospitality, and entertainment company with a portfolio of casinos and resorts and a growing omnichannel presence. It provides customers with physical and interactive entertainment and gaming experiences, including traditional casino offerings, iGaming, online bingo, sportsbook, and free-to-play (F2P) games. The company owns and operates, several casinos across the United States, one golf course in New York, one horse racetrack in Colorado, and Aspers Casino in the United Kingdom. Its Interactive International division, an interactive gaming operator concentrated in Europe, operates a lottery management and services business. The company's reportable segments are Casinos and Resorts, which derive key revenue, International Interactive and North America Interactive.